Kidney Derived Stem Cells

肾源性干细胞

• 批准号: 6809372
• 负责人: MARK E. ROSENBERG
• 金额: $ 14.85万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-01 至 2006-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6809372
• 关键词: acute renal failure; cell differentiation; flow cytometry; gene expression; genetically modified animals; immunofluorescence technique; kidney; kidney cell; laboratory mouse; laboratory rat; microarray technology; polymerase chain reaction; stem cells; technology /technique development; urinary bladder epithelium

DESCRIPTION (provided by applicant): Recovery of renal function following acute renal failure is dependent on the replacement of necrotic tubular cells with functioning renal epithelium. The source of these new tubular cells is thought to be adjacent, less damaged tubular cells although extrarenal cells contribute to some degree. We hypothesize that a stem cell is present in the adult kidney that can differentiate into the different cell lineages of the kidney. We have isolated and begun to characterize such stem cells derived from adult kidneys that we will refer to as multipotent renal progenitor cells (MRPCs). The source for MRPCs include adult mouse and rat kidneys derived from normal and transgenic animals. The goal of this developmental application is to further characterize these cells, and to use the cells in a culture system model to define factors responsible for cell lineage progression of renal cells. We propose to localize MRPCs in normal and injured adult kidneys and to perform fate mapping of these cells to determine if these cells contribute to tubular cell regeneration following acute tubular necrosis (ATN). We also propose to test whether injected cells at various stages of differentiation can be used as therapeutic agents for the treatment of kidney disease.

描述（由申请人提供）：急性肾衰竭后肾功能的恢复取决于用功能肾上皮的坏死管细胞的替代。这些新的管状细胞的来源被认为是相邻的，较少受损的管状细胞，尽管外部细胞在某种程度上贡献了一定程度。我们假设成年肾脏中存在一个干细胞，可以区分肾脏的不同细胞谱系。我们已经分离出来并开始表征从成年肾脏衍生的干细胞，我们将其称为多能肾脏祖细胞（MRPC）。 MRPC的来源包括成年小鼠和源自正常动物和转基因动物的大鼠肾脏。这种发育应用的目的是进一步表征这些细胞，并在培养系统模型中使用细胞来定义负责肾细胞细胞谱系进展的因素。我们建议将MRPC定位在正常和受伤的成年肾脏中，并进行这些细胞的命运图，以确定这些细胞在急性管状坏死后是否有助于管状细胞再生（ATN）。我们还建议测试是否可以将分化各个阶段的注射细胞用作治疗肾脏疾病的治疗剂。